Novo Nordisk: El ensayo clínico de fase 3 con semaglutida de 7.2 mg alcanzó el punto final principal, con una reducción del 20.7% en el peso a las 72 semanas.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.